PURPOSE: Effective therapeutic strategies that can achieve long-term improvement in patients with castration resistant prostate cancer are urgently needed. We recently reported that the activated PI3K/Akt/mTOR signaling pathway induced by docetaxel explains resistance to docetaxel in castration resistant prostate cancer. In this study we explored the efficacy of NVP-BEZ235, a dual PI3K and mTORC1/2 inhibitor, for docetaxel resistant castration resistant prostate cancer. MATERIALS AND METHODS: We used the 2 human castration resistant prostate cancer cell lines C4-2 and C4-2AT6. At our laboratory C4-2AT6 cells were established from C4-2 under androgen ablated treatment for 6 months. We investigated the efficacy of NVP-BEZ235 monotherapy and NVP-BEZ235 combined with docetaxel in vitro and in vivo. RESULTS: Increased phosphorylated Akt in C4-2AT6 cells was significantly inhibited by NVP-BEZ235 in a dose and time dependent manner. WST cell proliferation assay results in C4-2AT6 cells revealed that combined administration of NVP-BEZ235 and docetaxel had significant, synergistically greater cytotoxicity than NVP-BEZ235 or docetaxel monotherapy. Combined NVP-BEZ235 (40 mg/kg) and docetaxel (4 mg/kg) in vivo in a castrated mouse xenograft model inhibited C4-2AT6 tumor growth to a greater degree than in the monotherapy groups. Also, NVP-BEZ235 showed significant efficacy with docetaxel at a low concentration in vivo, suggesting that NVP-BEZ235 effectively decreased resistance to docetaxel. CONCLUSIONS: Results suggest that inhibition of the PI3K/Akt/mTOR signaling pathway by NVP-BEZ235 can overcome docetaxel resistance in human castration resistant prostate cancer. Our findings provide a molecular basis for the clinical use of combined administration of NVP-BEZ235 and docetaxel in patients with castration resistant prostate cancer.
PURPOSE: Effective therapeutic strategies that can achieve long-term improvement in patients with castration resistant prostate cancer are urgently needed. We recently reported that the activated PI3K/Akt/mTOR signaling pathway induced by docetaxel explains resistance to docetaxel in castration resistant prostate cancer. In this study we explored the efficacy of NVP-BEZ235, a dual PI3K and mTORC1/2 inhibitor, for docetaxel resistant castration resistant prostate cancer. MATERIALS AND METHODS: We used the 2 human castration resistant prostate cancer cell lines C4-2 and C4-2AT6. At our laboratory C4-2AT6 cells were established from C4-2 under androgen ablated treatment for 6 months. We investigated the efficacy of NVP-BEZ235 monotherapy and NVP-BEZ235 combined with docetaxel in vitro and in vivo. RESULTS: Increased phosphorylated Akt in C4-2AT6 cells was significantly inhibited by NVP-BEZ235 in a dose and time dependent manner. WST cell proliferation assay results in C4-2AT6 cells revealed that combined administration of NVP-BEZ235 and docetaxel had significant, synergistically greater cytotoxicity than NVP-BEZ235 or docetaxel monotherapy. Combined NVP-BEZ235 (40 mg/kg) and docetaxel (4 mg/kg) in vivo in a castrated mouse xenograft model inhibited C4-2AT6 tumor growth to a greater degree than in the monotherapy groups. Also, NVP-BEZ235 showed significant efficacy with docetaxel at a low concentration in vivo, suggesting that NVP-BEZ235 effectively decreased resistance to docetaxel. CONCLUSIONS: Results suggest that inhibition of the PI3K/Akt/mTOR signaling pathway by NVP-BEZ235 can overcome docetaxel resistance in human castration resistant prostate cancer. Our findings provide a molecular basis for the clinical use of combined administration of NVP-BEZ235 and docetaxel in patients with castration resistant prostate cancer.
Authors: Matthew T Jefferies; Adam C Cox; Boris Y Shorning; Valerie Meniel; David Griffiths; Howard G Kynaston; Matthew J Smalley; Alan R Clarke Journal: J Pathol Date: 2017-11-14 Impact factor: 7.996
Authors: Kevin D Courtney; Judith B Manola; Aymen A Elfiky; Robert Ross; William K Oh; Jeffrey T Yap; Annick D Van den Abbeele; Christopher W Ryan; Tomasz M Beer; Massimo Loda; Carmen Priolo; Philip Kantoff; Mary-Ellen Taplin Journal: Clin Genitourin Cancer Date: 2014-10-22 Impact factor: 2.872
Authors: Danielle M Burgenske; David J Monsma; Dawna Dylewski; Stephanie B Scott; Aaron D Sayfie; Donald G Kim; Martin Luchtefeld; Katie R Martin; Paul Stephenson; Galen Hostetter; Nadav Dujovny; Jeffrey P MacKeigan Journal: Am J Cancer Res Date: 2014-11-19 Impact factor: 6.166
Authors: Camila L Amaral; Lidia B Freitas; Rodrigo E Tamura; Mariana R Tavares; Isadora C B Pavan; Marcio C Bajgelman; Fernando M Simabuco Journal: BMC Cancer Date: 2016-08-05 Impact factor: 4.430
Authors: Du G Moon; Sang E Lee; Mi M Oh; Sang C Lee; Seong J Jeong; Sung K Hong; Cheol Y Yoon; Seok S Byun; Hong S Park; Jun Cheon Journal: Int J Oncol Date: 2014-06-19 Impact factor: 5.650